- ￥1712 - 46336
- BioXcell
- BE0101
- 美国
- 2025年07月16日
- in vivo PD-L1 blockade, Immunofluorescence, Immunohistochemistry (frozen), Flow cytometry
- Rat
- mouse
企业认证
相关产品推荐更多 >
V5-tag Recombinant monoclonal antibody (SV5-P-K) (Human IgG2κ)
￥7683.98Coronavirus (SARS-CoV Matrix) polyclonal antibody
￥7212.40β-galactosidase Recombinant monoclonal antibody (13R4) (Mouse IgG3λ)
￥7683.98Coronavirus (COVID-19, MERS and SARS-CoV NP) monoclonal antibody
￥7198.53c-Myc (human) Recombinant monoclonal antibody (9E10) (Rat IgG1κ)
￥7683.98
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 文献和实验
- 技术资料
- 抗体名：
InVivoMab anti-mouse PD-L1 (B7-H1)
- 抗体英文名：
InVivoMab anti-mouse PD-L1 (B7-H1)
- 靶点：
请见产品说明
- 浓度：
请见产品说明
- 应用范围：
in vivo PD-L1 blockade, Immunofluorescence, Immunohistochemistry (frozen), Flow cytometry
- 宿主：
Rat
- 适应物种：
mouse
- 保质期：
请见产品说明
- 抗原来源：
/
- 目录编号：
/
- 级别：
体内研究抗体
- 库存：
大量
- 供应商：
深圳欣博盛生物科技有限公司
- 标记物：
无
- 克隆性：
单克隆
- 保存条件：
4度避光
- 形态：
液体
- 亚型：
Rat IgG2b
- 免疫原：
mouse PD-L1 (B7-H1)
- 规格：
5 mg/1 mg/25 mg/50 mg/100 mg
| 规格： | 5 mg | 产品价格： | ￥6576.0 |
|---|---|---|---|
| 规格： | 1 mg | 产品价格： | ￥1712.0 |
| 规格： | 25 mg | 产品价格： | ￥22480.0 |
| 规格： | 50 mg | 产品价格： | ￥33152.0 |
| 规格： | 100 mg | 产品价格： | ￥46336.0 |
InVivoMab anti-mouse PD-L1 (B7-H1) 产品货号：BE0101 ，有五种规格可供选择。购买产品，咨询技术问题，请联系Bioxcell一级代理商，中国库存中心欣博盛生物。
BioXcell InVivoMab anti-mouse PD-L1 (B7-H1) 10F.9G2单克隆抗体与小鼠PD-L1（也称为B7-H1或CD274）反应。PD-L1是属于Ig超家族的B7家族的I型跨膜蛋白，分子量为40kDa。PD-L1在T淋巴细胞、B淋巴细胞、NK细胞、树突状细胞以及IFNγ刺激的单核细胞、上皮细胞和内皮细胞上表达。PD-L1与CD4和CD8胸腺细胞以及活化的T和B淋巴细胞和骨髓细胞上的受体PD-1结合。PD-L1与PD-1的结合导致抑制TCR介导的T细胞增殖和细胞因子产生。PD-L1被认为在肿瘤免疫逃避中起着重要作用。诱导的PD-L1表达在许多肿瘤中很常见，并导致肿瘤细胞对CD8 T细胞介导的裂解的抗性增加。在黑色素瘤的小鼠模型中，可以通过用阻断PD-L1和PD-1之间相互作用的抗体处理来暂时肿瘤生长。BioXcell InVivoMab anti-mouse PD-L1 (B7-H1) 10F.9G2抗体已被证明可以阻断PD-L1和PD-1之间以及PD-L1和B7-1之间的相互作用（CD80）。
产品详情：
| 产品名称 | InVivoMAb anti-mouse PD-L1 (B7-H1) |
| 产品货号 |
BE0101 |
| 产品规格 |
1/5/25/50/100mg |
| 反应种属 |
Mouse |
| 克隆号 |
10F.9G2 |
| 同种型 |
Rat IgG2a, κ |
| 免疫原 |
Mouse CD274 |
| 实验应用 |
in vivo PD-L1 blockade Immunofluorescence Immunohistochemistry (frozen) Flow cytometry Western blot |
| 产品形式 |
PBS, pH 6.5,Contains no stabilizers or preservatives |
| 纯度 |
>95%, Determined by SDS-PAGE |
| 无菌处理 |
0.2 µm filtration |
| 纯化方式 |
Protein G |
| RRID |
AB_10949073 |
| 分子量 |
150 kDa |
| 保存条件 |
抗体原液保存在4°C，不能冷冻保存。 |
| 推荐同型对照 |
InVivoMAb rat IgG2b isotype control, anti-keyhole limpet hemocyanin（货号BE0090） |
| 推荐抗体稀释液 |
InVivoPure pH 6.5 Dilution Buffer（货号IP0065） |
该产品自上市已被多篇SCI文献引用，品质有保证，以下是部分已发表的文献引用：
| 应用 |
文章 |
| 体内PD-L1信号阻断 (in vivo PD-L1 blockade) |
1. Grasselly, C., et al. (2018). 'The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent' Front Immunol 9: 2100. 2. Stathopoulou, C., et al. (2018). 'PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells' Immunity 49(2): 247-263 e247. 3. Jaworska, K., et al. (2015). 'Both PD-1 ligands protect the kidney from ischemia reperfusion injury' J Immunol 194(1): 325-333. 4. Kim, J., et al. (2015). 'Memory programming in CD8(+) T-cell differentiation is intrinsic and is not determined by CD4 help' Nat Commun 6: 7994. 5. Zander, R. A., et al. (2015). 'PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity' Cell Host Microbe 17(5): 628-641. 6. Tkachev, V., et al. (2015). 'Programmed death-1 controls T cell survival by regulating oxidative metabolism' J Immunol 194(12): 5789-5800. 7. Twyman-Saint Victor, C., et al. (2015). 'Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer' Nature 520(7547): 373-377.
|
| 体内PD-L1阻断，流式细胞术 (in vivo PD-L1 blockade, Flow Cytometry) |
1. loulou, M., et al. (2016). 'Follicular regulatory T cells can be specific for the immunizing antigen and derive from naive T cells' Nat Commun 7: 10579. 2. Ngiow, S. F., et al. (2015). 'A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1' Cancer Res 75(18): 3800-3811. 3. Rutigliano, J. A., et al. (2014). 'Highly pathological influenza A virus infection is associated with augmented expression of PD-1 by functionally compromised virus-specific CD8+ T cells' J Virol 88(3): 1636-1651. |
| 体内PD-L1阻断，免疫荧光 (in vivo PD-L1 blockade, Immunofluorescence) |
1.Willimsky, G., et al. (2013). 'Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance' J Clin Invest 123(3): 1032-1043. |
| 免疫组织化学（冷冻），免疫荧光 (Immunohistochemistry (frozen), Immunofluorescence ) |
1.Riella, L. V., et al. (2011). 'Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts' Am J Transplant 11(4): 832-840. |
更多产品详情请咨询 BioXcell 中国授权代理——欣博盛生物
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
文献和实验1. Grasselly, C., et al. (2018). 'The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent' Front Immunol 9: 2100.
2. Stathopoulou, C., et al. (2018). 'PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells' Immunity 49(2): 247-263 e247.
3. Jaworska, K., et al. (2015). 'Both PD-1 ligands protect the kidney from ischemia reperfusion injury' J Immunol 194(1): 325-333.
4. Kim, J., et al. (2015). 'Memory programming in CD8(+) T-cell differentiation is intrinsic and is not determined by CD4 help' Nat Commun 6: 7994.
5. Zander, R. A., et al. (2015). 'PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity' Cell Host Microbe 17(5): 628-641.
6. Tkachev, V., et al. (2015). 'Programmed death-1 controls T cell survival by regulating oxidative metabolism' J Immunol 194(12): 5789-5800.
7. Twyman-Saint Victor, C., et al. (2015). 'Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer' Nature 520(7547): 373-377.
了 B7 家族的第三个成员 B7-H1（即日后的 PD-L1）[2]。2000 年，Tasuku Honjo 教授等人证明了 PD-L1 能与 PD-1 结合，进而抑制 T 细胞的增殖与细胞因子的分泌，负调控淋巴细胞的激活，从此，B7-H1 被正式命名为 PD-L1（陈列平教授则继续使用「B7-H1」命名）[3]。2003年，陈列平教授第一次成功地使用 PD-L1 封闭抗体联合 T 细胞回输技术治愈了约 60% 的头颈癌小鼠[4]。2014 年 12 月，首个应用于肿瘤治疗的抗 PD-1 抗体
[J]． EMBO J, 1992,11(11):3887-2895. [2] Okazaki T, Wang J. PD-1/PD-L pathway and autoimmunity [J].Autoimmunity, 2005,38(5):353-357. [3] Okudaira K, Hokari R, Tsuzuki Y, et al． Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse
) A431 cells. At 48 h after infection, these cells were stained with ten different primary antibodies (5 g/ml) specific for different cell surface markers: anti-CD15 (clone 2F3; BD, PharMingen, San Diego, CA), anti-ERBB-2 (clone SP77; ref. 5), anti-ERBB
技术资料暂无技术资料 索取技术资料
